Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E41.08 EPS (ttm)1.53 Insider Own0.10% Shs Outstand2.70B Perf Week1.11%
Market Cap169.49B Forward P/E13.87 EPS next Y4.53 Insider Trans-11.56% Shs Float2.69B Perf Month0.48%
Income4.18B PEG6.21 EPS next Q1.03 Inst Own75.80% Short Float0.64% Perf Quarter10.01%
Sales40.73B P/S4.16 EPS this Y29.20% Inst Trans-0.04% Short Ratio1.63 Perf Half Y9.18%
Book/sh12.49 P/B5.04 EPS next Y7.19% ROA1.80% Target Price69.06 Perf Year0.00%
Cash/sh2.73 P/C23.07 EPS next 5Y6.62% ROE4.30% 52W Range52.83 - 66.41 Perf YTD11.76%
Dividend1.92 P/FCF1168.89 EPS past 5Y-1.90% ROI8.70% 52W High-5.30% Beta0.79
Dividend %3.05% Quick Ratio1.10 Sales past 5Y-3.20% Gross Margin68.60% 52W Low19.04% ATR0.84
Employees69000 Current Ratio1.40 Sales Q/Q6.40% Oper. Margin13.60% RSI (14)63.48 Volatility1.07% 1.26%
OptionableYes Debt/Eq0.70 EPS Q/Q-51.60% Profit Margin3.90% Rel Volume0.70 Prev Close62.66
ShortableYes LT Debt/Eq0.64 EarningsJul 27 BMO Payout326.40% Avg Volume10.51M Price62.89
Recom2.00 SMA202.58% SMA504.29% SMA2007.98% Volume7,352,346 Change0.37%
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Jan-12-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-12-17Upgrade Guggenheim Neutral → Buy
Jul-13-18 08:50AM  Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit Zacks
08:34AM  Dow 30 Stock Roundup: Boeing Q2 Commercial Deliveries Up Y/Y, Pfizer to Reorganize Zacks
08:05AM  Merck Financial Services GmbH -- Moody's affirms Merck KGaA's Baa1 ratings Moody's
Jul-12-18 09:20AM  Merck's Keytruda Gets FDA's Priority Review for Liver Cancer Zacks
Jul-11-18 12:53PM  Merck Stock Seen Rising 12% on Faster Profit Growth Investopedia
06:45AM  FDA Grants Priority Review to Mercks Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Hepatocellular Carcinoma Business Wire
06:30AM  After Trump Criticism, Pfizer Backtracks on Drug Price HikesFor Now Fortune
Jul-09-18 01:28PM  Pfizer shares rise after President Trump attacks its drug price hikes MarketWatch
09:57AM  Johnson & Johnson Stock Only Benefits from Big Moves That May Not Come InvestorPlace
Jul-06-18 06:48PM  Cramer's lightning round: Buy Merck on its superior anti-cancer portfolio CNBC
05:29PM  Is health care the ultimate hideout trade? CNBC Videos
11:54AM  Dont Buy Biogen Stock on the Promise of an Alzheimers Breakthrough InvestorPlace
09:16AM  Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs Zacks
09:13AM  Trade of the Day: Novocure Ltd (NVCR) InvestorPlace
08:57AM  Dow 30 Stock Roundup: Bell-Boeing JV's Navy Deal Win, Merck Keytruda's Priority Review Zacks
02:18AM  Hitting cancer early - AstraZeneca's bid to outmanoeuvre rivals Reuters
Jul-05-18 03:35PM  Fed minutes warn of rising trade risks Yahoo Finance Video
12:03PM  Pfizer's Stock Ready for a 10% Rebound Investopedia
11:46AM  Go Long Pfizer Stock Its an Easy Pill to Swallow InvestorPlace
Jul-03-18 10:10AM  Merck's Keytruda Gets Priority Review in Difficult Lung Cancer Zacks
06:00AM  10 Dow Stocks to Buy for the Second Half of 2018 Investopedia
02:30AM  Germany's Merck sees performance materials unit turning corner in 2020 Reuters
Jul-02-18 06:45AM  FDA Grants Priority Review to Mercks Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy as First-Line Treatment for Metastatic Squamous Non-Small Cell Lung Cancer Business Wire
06:30AM  Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018 Business Wire
02:00AM  LYNPARZA® (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer Business Wire
Jun-29-18 09:57AM  Interested In Pharmaceutical Stocks? Try Novartis (ADR) Investopedia
07:00AM  Blog Exposure AstraZenecas LYNPARZA(R) Reports Encouraging Results from Phase-III 1st-Line SOLO-1 Trial for Advanced Ovarian Cancer ACCESSWIRE
Jun-28-18 07:00PM  FOCUS-AI ambulances and robot doctors: China seeks digital salve to ease hospital strain Reuters
10:04AM  UPDATE 1-U.S. Supreme Court to hear Merck appeal over Fosamax suits Reuters
09:49AM  AI ambulances and robot doctors: China seeks digital salve to ease hospital strain Reuters
08:30AM  Amgen Announces Top-Line Data From Remicade Biosimilar Study Zacks
Jun-27-18 05:00PM  Merck Announces Findings from WHO-led Study of Investigational Heat-Stable Carbetocin for Preventing Excessive Bleeding After Childbirth Business Wire
12:03PM  [$$] One Year After NotPetya, Companies Still Wrestle With Financial Impacts The Wall Street Journal
07:00AM  Wired News - Merck Announces FDA Acceptance of Supplemental Biologics License Application for KEYTRUDA® as Adjuvant Therapy in Advanced Melanoma ACCESSWIRE
07:00AM  REPEAT/LYNPARZA® (olaparib) Significantly Delays Disease Progression in Phase 3 First-Line SOLO-1 Trial for Ovarian Cancer Business Wire
06:45AM  Merck to Hold Second-Quarter 2018 Sales and Earnings Conference Call on July 27 Business Wire
05:14AM  AstraZeneca, Merck eye $1 billion boost from cancer drug success Reuters
05:04AM  AstraZeneca, Merck eye $1 bln boost from cancer drug success Reuters
03:19AM  AstraZeneca, Merck eye wider cancer drug use after study success Reuters
Jun-26-18 11:16AM  Merck's Keytruda Under FDA Review for Advanced Melanoma Zacks
07:00AM  Stock Performance Review on Pfizer and Three Other Drug Makers Stocks ACCESSWIRE
06:31AM  3 Best Big Pharma Stocks of 2018 So Far Motley Fool
Jun-25-18 06:21PM  Theres Massive Demand for GlaxoSmithKlines Shingles VaccineAnd Its Causing a Shortfall Fortune
11:46AM  Merck (MRK) Presents New Data from Januvia Diabetes Studies Zacks
09:41AM  Clamour for GSK shingles shot points to bigger profits Reuters
07:17AM  Clamour for GSK shingles shot points to bigger profits Reuters
06:30AM  FDA Accepts Supplemental Biologics License Application for Mercks KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Advanced Melanoma Business Wire
Jun-23-18 10:00AM  Merck Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA® (sitagliptin) Business Wire
Jun-22-18 08:37PM  [$$] Vaccine Expert Adel Mahmoud Took Up the Worlds Problems The Wall Street Journal
08:02PM  Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma TheStreet.com
09:50AM  Merck (MRK) Stock Up So Far This Year on Keytruda Strength Zacks
08:10AM  Is It Time To Sell Merck & Co Inc (NYSE:MRK) Based Off Its PE Ratio? Simply Wall St.
06:04AM  U.S. medical device firm electroCore IPO price set at $15/shr Reuters
Jun-21-18 05:33PM  Novo Nordisk Stock Rises 4% Over 2 Sessions TheStreet.com
Jun-20-18 04:26PM  What GEs stock being replaced by Walgreens in the Dow Jones Industrial Average may mean MarketWatch
04:26AM  [$$] Wednesday's European Corporate Roundup The Wall Street Journal
02:02AM  Latecomer Sanofi looks to catch next wave of cancer therapies Reuters
Jun-19-18 08:16AM  Better Buy: Celgene Corporation vs. Merck Motley Fool
Jun-18-18 06:00PM  In China, Baijiu and HPV Vaccines Have Something in Common Bloomberg
07:00AM  The Blockchain Revolution Has Just Begun InvestorPlace
06:00AM  5 Drug Stocks With Fat Payouts Investopedia
Jun-15-18 11:52AM  7 Perfect Dividend Stocks InvestorPlace
10:56AM  Affimed Shares Slide On Updated Hodgkin Lymphoma Drug Combo Data Benzinga
10:13AM  Top Ranked Income Stocks to Buy for June 15th Zacks
09:27AM  Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals Zacks
09:25AM  Dow 30 Stock Roundup: Caterpillar Raises Dividend, Merck's Keytruda Gets FDA Nod Zacks
Jun-14-18 09:09PM  Does Merck & Co Inc.s (NYSE:MRK) PE Ratio Signal A Selling Opportunity? Simply Wall St.
12:05PM  3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry InvestorPlace
08:30AM  Merck's Keytruda Gets FDA Nod for 2nd Lymphoma Indication Zacks
08:11AM  Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi Benzinga
06:54AM  Merck (MRK): Moving Average Crossover Alert Zacks
Jun-13-18 05:00PM  China's Vaccine Tourists Drain Hong Kong's Supply of Cancer Drug Bloomberg
04:06PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL) Business Wire
10:37AM  Merck's (MRK) Keytruda Gets FDA Approval for Cervical Cancer Zacks
06:45AM  FDA Grants Priority Review to Mercks Supplemental Biologics License Application (sBLA) for GARDASIL®9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases Business Wire
Jun-12-18 04:06PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) Business Wire
10:24AM  Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate Zacks
09:25AM  Alzheimer's Research Stumbles Again: What's the Road Ahead? Zacks
07:14AM  Top Ranked Income Stocks to Buy for June 12th Zacks
Jun-11-18 01:12PM  Mega Caps Are Soaring in June: 3 Top-Ranked Stocks on Sale InvestorPlace
Jun-08-18 12:20PM  The CEO Action for Diversity and Inclusion Turns Two Fortune
09:14AM  An Unlikely Biotech Investor: The Government Forbes
08:05AM  The Zacks Analyst Blog Highlights: Merck, Occidental Petroleum, Capital One Financial, Kimberly-Clark and Allstate Zacks
Jun-07-18 02:47PM  Top Analyst Reports for Merck, Occidental Petroleum & Capital One Financial Zacks
09:30AM  Is Merck & Co. (MRK) Outperforming Other Medical Stocks This Year? Zacks
Jun-06-18 08:29AM  ASCO Ends: Winners & Losers at the Key Cancer Research Event Zacks
Jun-05-18 05:26PM  Sanofi, Merck and J&J Tout Lower Drug Prices TheStreet.com
12:16PM  Pharma Giant Merck Is Planning for a Brexit Supply Blackout Bloomberg
12:16PM  Merck Is Said to Prepare for Supply Blackout in Brexit Planning Bloomberg
10:56AM  Merck Presents Positive Melanoma Data on Keytruda at ASCO Zacks
Jun-04-18 07:45PM  Research Yields Progress Against Lung Cancer The Wall Street Journal
05:00PM  LYNPARZA® (olaparib) in Combination with Abiraterone Delayed Disease Progression in Metastatic Castration-Resistant Prostate Cancer Business Wire
11:55AM  Merck Higher on Lung Cancer Data TheStreet.com
10:57AM  Merck's (MRK) Keytruda Lung Cancer Data in Focus at ASCO Zacks
09:39AM  3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry Zacks
09:00AM  Two Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab) CNW Group
08:30AM  Today's Research Reports on Trending Tickers: Merck & Co. and Pfizer Inc. ACCESSWIRE
08:16AM  Merck's Keytruda shows promise in treating advanced melanoma Reuters
07:45AM  Mercks KEYTRUDA® (pembrolizumab) Showed Promising Anti-Tumor Activity in Patients with Advanced Small Cell Lung Cancer (SCLC) in Phase 2 KEYNOTE-158 Study Business Wire
07:41AM  Merck announces positive results for Keytruda in melanoma trial MarketWatch
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., IO Biotech, and Premier Inc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schechter Adam HEVP & Pres-Global Human HealthJun 18Option Exercise36.56100,0003,656,000100,000Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.0034,0942,079,78562,766Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.00100,0006,100,1600Jun 19 10:55 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 15Sale59.669,972594,96345,717May 16 12:33 PM
Watson AshleySVP Chief Ethics & Com OfficerMay 01Option Exercise0.0010,441012,783May 02 12:19 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 01Option Exercise0.004,009052,609May 02 12:18 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise0.003,007022,205May 02 12:18 PM
GRADDICK WEIR MIRIAN MExe V-P, HRApr 16Sale58.0024,0001,392,00080,433Apr 17 05:56 PM
WEEKS WENDELL PDirectorFeb 09Option Exercise38.045,000190,2005,100Feb 09 04:48 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthFeb 09Option Exercise0.008,572045,780Feb 09 04:48 PM
WEEKS WENDELL PDirectorFeb 09Sale53.575,000267,833100Feb 09 04:48 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Option Exercise36.5650,9941,864,34150,994Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Option Exercise44.3052,0002,303,600153,484Jan 16 05:12 PM
Holston Michael JEVP, General CounselJan 16Sale61.6312,500770,37549,092Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,6083,118,97162,766Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,9943,142,7600Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Sale61.6360,0003,697,80093,484Jan 16 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 12Sale58.005,000290,000101,484Jan 16 05:12 PM
GLOCER THOMAS HDirectorNov 08Option Exercise38.045,000190,20010,100Nov 09 03:52 PM
GLOCER THOMAS HDirectorNov 08Sale56.205,000280,9835,100Nov 09 03:52 PM